世界の注意欠陥多動性障害（ADHD）治療市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z0504 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、95ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥546,000 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥819,000 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,092,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査資料では、注意欠陥多動性障害（ADHD）治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（刺激剤、非刺激剤）、用途別市場規模（専門クリニック、病院薬局、小売薬局、Eコマース）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・注意欠陥多動性障害（ADHD）治療の市場動向 ・企業の競争状況、市場シェア ・注意欠陥多動性障害（ADHD）治療の種類別市場規模（刺激剤、非刺激剤） ・注意欠陥多動性障害（ADHD）治療の用途別市場規模（専門クリニック、病院薬局、小売薬局、Eコマース） ・注意欠陥多動性障害（ADHD）治療の北米市場規模2016-2027（アメリカ、カナダ） ・注意欠陥多動性障害（ADHD）治療のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・注意欠陥多動性障害（ADHD）治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・注意欠陥多動性障害（ADHD）治療の中南米市場規模2016-2027（メキシコ、ブラジル） ・注意欠陥多動性障害（ADHD）治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Eli Lilly and Company、Novartis、Takeda、Pfizer、GlaxoSmithKline、Mallinckrodt Pharmaceuticals、Hisamitsu Pharmaceutical、Impax Laboratories、Johnson ＆Johnson、UCB、Purdue Parma） ・結論

ADHD is a brain/neurodevelopmental/neurobehavioral disorder characterized by pervasive and impairing symptoms of inattention, hyperactivity, and impulsivity. The Centers for Disease Control and Prevention (CDC) defines “neurobehavioral” as the way the brain affects emotion, behavior, and learning.
Growth in the ADHD therapeutics market is mainly driven by granular impact of changing lifestyles and value systems impacting quality of births, increasing use of additives and preservations in children’s diet, rising prevalence of ADHD among children in the 4–17 year age group, increasing adoption of diagnostic guidelines (statistical manual of mental disorders) with low threshold for diagnosis of ADHD in other regions such as Europe and Latin America. Moreover, increasing awareness regarding ADHD among physicians and patients, and opinion-based diagnosis of ADHD owing to lack of standard diagnostic tests is expected to boost revenue growth of the global ADHD therapeutics market in the near future. However, existence of comorbid conditions in children leads to underdiagnoses of ADHD and less availability of non-stimulants ADHD drugs in various geographies. These are factors expected to restrain growth of the market over the forecast period.

Market Analysis and Insights: Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market
The global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics market.

Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Scope and Market Size
Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Stimulants
Non-Stimulants

Segment by Application
Specialty Clinics
Hospital Pharmacies
Retail Pharmacies
E-Commerce

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Eli Lilly and Company
Novartis
Takeda
Pfizer
GlaxoSmithKline
Mallinckrodt Pharmaceuticals
Hisamitsu Pharmaceutical
Impax Laboratories
Johnson ＆Johnson

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Stimulants
1.2.3 Non-Stimulants
1.3 Market by Application
1.3.1 Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Specialty Clinics
1.3.3 Hospital Pharmacies
1.3.4 Retail Pharmacies
1.3.5 E-Commerce
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Perspective (2016-2027)
2.2 Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Growth Trends by Regions
2.2.1 Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Historic Market Share by Regions (2016-2021)
2.2.3 Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Forecasted Market Size by Regions (2022-2027)
2.3 Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Industry Dynamic
2.3.1 Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Trends
2.3.2 Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Drivers
2.3.3 Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Challenges
2.3.4 Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Players by Revenue
3.1.1 Global Top Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Players by Revenue (2016-2021)
3.1.2 Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share by Players (2016-2021)
3.2 Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue
3.4 Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Concentration Ratio
3.4.1 Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue in 2020
3.5 Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Key Players Head office and Area Served
3.6 Key Players Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Product Solution and Service
3.7 Date of Enter into Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Breakdown Data by Type
4.1 Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Historic Market Size by Type (2016-2021)
4.2 Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Forecasted Market Size by Type (2022-2027)

5 Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Breakdown Data by Application
5.1 Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Historic Market Size by Application (2016-2021)
5.2 Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size (2016-2027)
6.2 North America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Type
6.2.1 North America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Type (2016-2021)
6.2.2 North America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Type (2022-2027)
6.2.3 North America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Type (2016-2027)
6.3 North America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Application
6.3.1 North America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Application (2016-2021)
6.3.2 North America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Application (2022-2027)
6.3.3 North America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Application (2016-2027)
6.4 North America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country
6.4.1 North America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2016-2021)
6.4.2 North America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size (2016-2027)
7.2 Europe Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Type
7.2.1 Europe Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Type (2016-2021)
7.2.2 Europe Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Type (2022-2027)
7.2.3 Europe Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Type (2016-2027)
7.3 Europe Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Application
7.3.1 Europe Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Application (2016-2021)
7.3.2 Europe Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Application (2022-2027)
7.3.3 Europe Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Application (2016-2027)
7.4 Europe Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country
7.4.1 Europe Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2016-2021)
7.4.2 Europe Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size (2016-2027)
8.2 Asia-Pacific Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Type
8.2.1 Asia-Pacific Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Type (2016-2027)
8.3 Asia-Pacific Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Application
8.3.1 Asia-Pacific Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Application (2016-2027)
8.4 Asia-Pacific Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Region
8.4.1 Asia-Pacific Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size (2016-2027)
9.2 Latin America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Type
9.2.1 Latin America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Type (2016-2021)
9.2.2 Latin America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Type (2022-2027)
9.2.3 Latin America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Type (2016-2027)
9.3 Latin America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Application
9.3.1 Latin America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Application (2016-2021)
9.3.2 Latin America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Application (2022-2027)
9.3.3 Latin America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Application (2016-2027)
9.4 Latin America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country
9.4.1 Latin America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2016-2021)
9.4.2 Latin America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size (2016-2027)
10.2 Middle East & Africa Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Type
10.2.1 Middle East & Africa Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Type (2016-2027)
10.3 Middle East & Africa Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Application
10.3.1 Middle East & Africa Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Application (2016-2027)
10.4 Middle East & Africa Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country
10.4.1 Middle East & Africa Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Eli Lilly and Company
11.1.1 Eli Lilly and Company Company Details
11.1.2 Eli Lilly and Company Business Overview
11.1.3 Eli Lilly and Company Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Introduction
11.1.4 Eli Lilly and Company Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2016-2021)
11.1.5 Eli Lilly and Company Recent Development
11.2 Novartis
11.2.1 Novartis Company Details
11.2.2 Novartis Business Overview
11.2.3 Novartis Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Introduction
11.2.4 Novartis Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2016-2021)
11.2.5 Novartis Recent Development
11.3 Takeda
11.3.1 Takeda Company Details
11.3.2 Takeda Business Overview
11.3.3 Takeda Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Introduction
11.3.4 Takeda Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2016-2021)
11.3.5 Takeda Recent Development
11.4 Pfizer
11.4.1 Pfizer Company Details
11.4.2 Pfizer Business Overview
11.4.3 Pfizer Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Introduction
11.4.4 Pfizer Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2016-2021)
11.4.5 Pfizer Recent Development
11.5 GlaxoSmithKline
11.5.1 GlaxoSmithKline Company Details
11.5.2 GlaxoSmithKline Business Overview
11.5.3 GlaxoSmithKline Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Introduction
11.5.4 GlaxoSmithKline Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2016-2021)
11.5.5 GlaxoSmithKline Recent Development
11.6 Mallinckrodt Pharmaceuticals
11.6.1 Mallinckrodt Pharmaceuticals Company Details
11.6.2 Mallinckrodt Pharmaceuticals Business Overview
11.6.3 Mallinckrodt Pharmaceuticals Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Introduction
11.6.4 Mallinckrodt Pharmaceuticals Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2016-2021)
11.6.5 Mallinckrodt Pharmaceuticals Recent Development
11.7 Hisamitsu Pharmaceutical
11.7.1 Hisamitsu Pharmaceutical Company Details
11.7.2 Hisamitsu Pharmaceutical Business Overview
11.7.3 Hisamitsu Pharmaceutical Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Introduction
11.7.4 Hisamitsu Pharmaceutical Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2016-2021)
11.7.5 Hisamitsu Pharmaceutical Recent Development
11.8 Impax Laboratories
11.8.1 Impax Laboratories Company Details
11.8.2 Impax Laboratories Business Overview
11.8.3 Impax Laboratories Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Introduction
11.8.4 Impax Laboratories Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2016-2021)
11.8.5 Impax Laboratories Recent Development
11.9 Johnson ＆Johnson
11.9.1 Johnson ＆Johnson Company Details
11.9.2 Johnson ＆Johnson Business Overview
11.9.3 Johnson ＆Johnson Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Introduction
11.9.4 Johnson ＆Johnson Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2016-2021)
11.9.5 Johnson ＆Johnson Recent Development
11.10 UCB
11.10.1 UCB Company Details
11.10.2 UCB Business Overview
11.10.3 UCB Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Introduction
11.10.4 UCB Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2016-2021)
11.10.5 UCB Recent Development
11.11 Purdue Parma
11.11.1 Purdue Parma Company Details
11.11.2 Purdue Parma Business Overview
11.11.3 Purdue Parma Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Introduction
11.11.4 Purdue Parma Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2016-2021)
11.11.5 Purdue Parma Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Stimulants
Table 3. Key Players of Non-Stimulants
Table 4. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 5. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Regions (2016-2021) & (US$ Million)
Table 7. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Regions (2016-2021)
Table 8. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 9. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Regions (2022-2027)
Table 10. Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Trends
Table 11. Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Drivers
Table 12. Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Challenges
Table 13. Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Restraints
Table 14. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Players (2016-2021) & (US$ Million)
Table 15. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Players (2016-2021)
Table 16. Global Top Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics as of 2020)
Table 17. Ranking of Global Top Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Companies by Revenue (US$ Million) in 2020
Table 18. Global 5 Largest Players Market Share by Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (CR5 and HHI) & (2016-2021)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Product Solution and Service
Table 21. Date of Enter into Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 24. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share by Type (2016-2021)
Table 25. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 26. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 27. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size Share by Application (2016-2021) & (US$ Million)
Table 28. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share by Application (2016-2021)
Table 29. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 30. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 31. North America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 32. North America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 33. North America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 34. North America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 35. North America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 36. North America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 37. Europe Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 38. Europe Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 39. Europe Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 40. Europe Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 41. Europe Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 42. Europe Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 43. Asia-Pacific Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 44. Asia-Pacific Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 46. Asia-Pacific Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Region (2016-2021) & (US$ Million)
Table 48. Asia-Pacific Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Region (2022-2027) & (US$ Million)
Table 49. Latin America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 50. Latin America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 51. Latin America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 52. Latin America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 53. Latin America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 54. Latin America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 55. Middle East & Africa Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 56. Middle East & Africa Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 58. Middle East & Africa Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 60. Middle East & Africa Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 61. Eli Lilly and Company Company Details
Table 62. Eli Lilly and Company Business Overview
Table 63. Eli Lilly and Company Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Product
Table 64. Eli Lilly and Company Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2016-2021) & (US$ Million)
Table 65. Eli Lilly and Company Recent Development
Table 66. Novartis Company Details
Table 67. Novartis Business Overview
Table 68. Novartis Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Product
Table 69. Novartis Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2016-2021) & (US$ Million)
Table 70. Novartis Recent Development
Table 71. Takeda Company Details
Table 72. Takeda Business Overview
Table 73. Takeda Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Product
Table 74. Takeda Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2016-2021) & (US$ Million)
Table 75. Takeda Recent Development
Table 76. Pfizer Company Details
Table 77. Pfizer Business Overview
Table 78. Pfizer Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Product
Table 79. Pfizer Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2016-2021) & (US$ Million)
Table 80. Pfizer Recent Development
Table 81. GlaxoSmithKline Company Details
Table 82. GlaxoSmithKline Business Overview
Table 83. GlaxoSmithKline Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Product
Table 84. GlaxoSmithKline Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2016-2021) & (US$ Million)
Table 85. GlaxoSmithKline Recent Development
Table 86. Mallinckrodt Pharmaceuticals Company Details
Table 87. Mallinckrodt Pharmaceuticals Business Overview
Table 88. Mallinckrodt Pharmaceuticals Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Product
Table 89. Mallinckrodt Pharmaceuticals Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2016-2021) & (US$ Million)
Table 90. Mallinckrodt Pharmaceuticals Recent Development
Table 91. Hisamitsu Pharmaceutical Company Details
Table 92. Hisamitsu Pharmaceutical Business Overview
Table 93. Hisamitsu Pharmaceutical Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Product
Table 94. Hisamitsu Pharmaceutical Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2016-2021) & (US$ Million)
Table 95. Hisamitsu Pharmaceutical Recent Development
Table 96. Impax Laboratories Company Details
Table 97. Impax Laboratories Business Overview
Table 98. Impax Laboratories Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2016-2021) & (US$ Million)
Table 99. Impax Laboratories Recent Development
Table 100. Johnson ＆Johnson Company Details
Table 101. Johnson ＆Johnson Business Overview
Table 102. Johnson ＆Johnson Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Product
Table 103. Johnson ＆Johnson Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2016-2021) & (US$ Million)
Table 104. Johnson ＆Johnson Recent Development
Table 105. UCB Company Details
Table 106. UCB Business Overview
Table 107. UCB Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Product
Table 108. UCB Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2016-2021) & (US$ Million)
Table 109. UCB Recent Development
Table 110. Purdue Parma Company Details
Table 111. Purdue Parma Business Overview
Table 112. Purdue Parma Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Product
Table 113. Purdue Parma Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2016-2021) & (US$ Million)
Table 114. Purdue Parma Recent Development
Table 115. Research Programs/Design for This Report
Table 116. Key Data Information from Secondary Sources
Table 117. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Type: 2020 VS 2027
Figure 2. Stimulants Features
Figure 3. Non-Stimulants Features
Figure 4. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Application: 2020 VS 2027
Figure 5. Specialty Clinics Case Studies
Figure 6. Hospital Pharmacies Case Studies
Figure 7. Retail Pharmacies Case Studies
Figure 8. E-Commerce Case Studies
Figure 9. Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Report Years Considered
Figure 10. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 11. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Regions: 2020 VS 2027
Figure 13. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Regions (2022-2027)
Figure 14. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Players in 2020
Figure 15. Global Top Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics as of 2020
Figure 16. The Top 10 and 5 Players Market Share by Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue in 2020
Figure 17. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share by Type (2016-2021)
Figure 18. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share by Type (2022-2027)
Figure 19. North America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 20. North America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Type (2016-2027)
Figure 21. North America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Application (2016-2027)
Figure 22. North America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Country (2016-2027)
Figure 23. United States Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Canada Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Type (2016-2027)
Figure 27. Europe Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Application (2016-2027)
Figure 28. Europe Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Country (2016-2027)
Figure 29. Germany Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. France Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. U.K. Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Italy Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Russia Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Nordic Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Type (2016-2027)
Figure 37. Asia-Pacific Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Application (2016-2027)
Figure 38. Asia-Pacific Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Region (2016-2027)
Figure 39. China Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Japan Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. South Korea Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Southeast Asia Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. India Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Australia Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Type (2016-2027)
Figure 47. Latin America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Application (2016-2027)
Figure 48. Latin America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Country (2016-2027)
Figure 49. Mexico Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Brazil Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Type (2016-2027)
Figure 53. Middle East & Africa Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Application (2016-2027)
Figure 54. Middle East & Africa Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Country (2016-2027)
Figure 55. Turkey Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Saudi Arabia Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. UAE Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Eli Lilly and Company Revenue Growth Rate in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2016-2021)
Figure 59. Novartis Revenue Growth Rate in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2016-2021)
Figure 60. Takeda Revenue Growth Rate in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2016-2021)
Figure 61. Pfizer Revenue Growth Rate in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2016-2021)
Figure 62. GlaxoSmithKline Revenue Growth Rate in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2016-2021)
Figure 63. Mallinckrodt Pharmaceuticals Revenue Growth Rate in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2016-2021)
Figure 64. Hisamitsu Pharmaceutical Revenue Growth Rate in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2016-2021)
Figure 65. Impax Laboratories Revenue Growth Rate in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2016-2021)
Figure 66. Johnson ＆Johnson Revenue Growth Rate in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2016-2021)
Figure 67. UCB Revenue Growth Rate in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2016-2021)
Figure 68. Purdue Parma Revenue Growth Rate in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2016-2021)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed

---